Cardior Pharmaceuticals: Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study

Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the CE marking of its PCR kit which

Related Keywords

,Kostenloser Wertpapierhandel ,Thomas Thum ,Eva Mulder ,Claudia Ulbrich Eva ,Cardior Pharmaceuticals Gmb ,Trophic Communications ,Cardior Pharmaceuticals ,European Heart Journalin ,Claudia Ulbrich Eva Stra ,Pharmaceuticals Gmbh ,Cardior ,Pharmaceuticals ,Nnounces ,Parking ,Ardiorhealth ,Ased ,Ngoing ,Prevert ,Hase ,Linical ,Study ,